This phase I dose escalation study evaluated the safety and tolerability of intravenous Viscum album L. (mistletoe) extract in 21 cancer patients. The doses ranged from 200 mg to 2000 mg, with the highest dose well tolerated, causing only mild allergic reactions and moderate fever in some patients. The study
